Mayo Clinic's manufacturing engineers on the cusp of delivering new biotherapies
Manufacturing engineers are at the forefront of bringing new medicines derived from human sources such as cells, blood and genes to patients, Mayo Clinic has said.
They produce what are often first-of-their kind biotherapies for diseases that previously had few or no treatment options.
"The most interesting thing about our job is being able to be part of a team that brings transformative cell-based therapies to the clinic," says Kyle Ecker, Advanced Biomanufacturing Engineer Supervisor at Mayo Clinic in Florida.
"It's incredibly fulfilling to understand the scientific basis of these therapies and watch them come to life by manufacturing products for individual patients."
Mayo Clinic's Center for Regenerative Biotherapeutics has 40 manufacturing engineers in Rochester and Florida. Their work makes it possible for researchers to conduct studies that require cells to be engineered on a very short timeline.
In some cases, they've been able to have cells taken from patients, manufactured and returned to them in a few weeks or less. Chimeric antigen receptor (CAR-T) cell therapy for B-cell cancers and a cell-based vaccine for ovarian cancer are two examples of experimental biotherapies manufactured at Mayo Clinic.
"Our engineering teams are very dedicated to patients. They know the importance of their job, and that's to get these drugs manufactured successfully so they can be given to patients in clinical trials," says Snigdha Rai, senior director of advanced biomanufacturing in the Center for Regenerative Biotherapeutics. "Without the engineers there would be no biomanufacturing and no cell and gene therapies for patients."
Manufacturing engineers work within a highly controlled laboratory setting or "clean room.' Clean rooms are facilities that operate according to current Good Manufacturing Practice (cGMP) regulations to ensure therapies are consistently manufactured and meet strict quality standards. These controlled environments have powerful purification systems to filter out pollutants such as dust, airborne particles, bacteria, fungus and mold that could compromise drug safety.
Adherence to strict cleanliness guidelines dictates how engineers do their job. Before stepping into a clean room, they train extensively how to operate in a cGMP facility without triggering contamination. They perform techniques to keep everything extremely clean or sterile, using high dexterity skills such as taking the cap off a vial and putting it back on with one hand, while the other hand fills it with a chemical compound.
They dress in coveralls or a "bunny suit" with a hood, goggles, face shield, double gloves and boot covers to block any escape of hair or skin cells. Once they've entered the clean room, their movements are slow and intentional.
"Rapid movements or quick opening of doors could trigger the sensors that monitor for microscopic particles," Ecker explains. "People and materials must flow in a specific path to prevent any type of contamination. For example, we move in one direction, entering the clean room through one door while exiting through a separate door."
Manufacturing engineers have the pivotal role of being the first to run processes that transform a cell and gene therapy from a discovery into experimental medicine for use in human clinical trials. They strictly follow standard operating procedures — a blueprint of sorts — to mass produce a new therapy. A minimum of two engineers work together at all times to ensure all cells are processed according to regulatory and quality standards.
"The team works very closely each step of the way. We check each other's work and keep detailed records confirming that all procedures have been completed," says Qing Cindy Shao, Ph.D., lead advanced biomanufacturing engineer. "There is no room for error."
An important function of the job is identifying when a procedure doesn't work as intended. The therapy is then sent back to the investigator and process development group to troubleshoot the issue and make appropriate changes. On-site manufacturing facilities make it possible to address the errors early and resolve them quickly. That helps minimize delays for patients.
"Our manufacturing engineers are indispensable. They work with quality control, quality assurance and process development to ensure the therapy meets the requirements and are safe for patients," says Alina Oancea, manager of cGMP manufacturing. "When the processes work as intended, it takes about two weeks to manufacture a CAR-T cell product."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Trade Arabia
4 days ago
- Trade Arabia
Cisco launches Quantum Entanglement Chip and research lab
Cisco has announced the development of quantum networking technology that lays the foundation for the quantum internet, potentially bringing practical quantum computing forward by decades, accelerating the timeline for real-world quantum computing and networking applications to just 5 - 10 years. As part of this initiative, Cisco has introduced its Quantum Network Entanglement Chip, a research prototype designed to scale quantum networks and interconnect quantum processors for meaningful, practical use. The company also announced the launch of the Cisco Quantum Labs, a dedicated research facility in Santa Monica, California, where Cisco's quantum scientists and engineers are developing next-generation quantum networking technologies. Mohannad Abuissa, Director of Solutions Engineering at Cisco Middle East, Africa, Türkiye, Romania, and CIS, commented: 'Quantum computing holds the promise to solve problems that are beyond the reach of even today's most powerful supercomputers. With our Quantum Network Entanglement Chip and the launch of Cisco Quantum Labs, we are laying the groundwork for scalable, real-world quantum networks. This is not just about preparing for the future, it's about enabling breakthroughs in security, communication, and computing that can begin delivering value today.' The Quantum Network Entanglement Chip Developed in collaboration with UC Santa Barbara, Cisco's Quantum Network Entanglement Chip is a research prototype that generates pairs of entangled photons, enabling instantaneous connection regardless of distance through quantum teleportation. Key differentiators of the chip include: • Works with existing infrastructure: Operates at standard telecom wavelengths and can therefore leverage existing fiber optic infrastructure • Practical deployment: Functions at room temperature as a miniaturized Photonic Integrated Chip (PIC), making it suitable for scalable system deployment today • Energy efficiency: Consumes less than 1mW of power • High performance: 1 million high-fidelity entanglement pairs per output channel, with a rate of up to 200 million entanglement pairs per second in chip Much like classical computing evolved by connecting smaller nodes into distributed data centers, the future of quantum will follow a similar trajectory. Rather than focusing on a single monolithic quantum computer, companies building quantum processors will benefit from Cisco's quantum networking technologies to scale their systems. By building this infrastructure now, Cisco is helping to accelerate the entire quantum ecosystem. From Lab to Reality The Cisco Quantum Labs facility in Santa Monica will serve as a facility where Cisco researchers can experiment with quantum networking solutions that bridge both theoretical concepts and practical implementation. Beyond the entanglement chip, Cisco is using the lab to advance research prototypes of other critical components to meet their vision of the quantum networking stack, including entanglement distribution protocols, a distributed quantum computing compiler, Quantum Network Development Kit (QNDK), and a Quantum Random Number Generator (QRNG) using quantum vacuum noise. In parallel, Cisco is implementing Post-Quantum Cryptography (PQC) NIST standards across their portfolio, ensuring classical networks remain secure in a post-quantum world. Advancing Quantum Networking in Two Strategic Directions Cisco's quantum networking roadmap follows two strategic paths: • Quantum Network for the Quantum World: Cisco is building infrastructure to connect quantum processors at scale, enabling distributed quantum computing, quantum sensing, and optimization algorithms that could transform critical applications such as drug discovery, materials science, and complex logistics problems. Their quantum network entanglement chip is foundational to this vision. • Quantum Network for the Classical World: While practical quantum computing problems might be a few years away, quantum networking principles offer immediate benefits to classical systems through use cases such as eavesdropper-proof secure communication, ultra-precise time synchronization, decision signaling, and secure location verification.
Trade Arabia
5 days ago
- Trade Arabia
TAQA appoints new Executive VP of Products & Technologies and CTO
Industrialization and Energy Services Company (TAQA), a global leader in energy and industrial services, has welcomed Jeff Lembcke to TAQA as Executive Vice President of Products & Technologies and Chief Technology Officer. Lembcke brings to TAQA more than four decades of global experience in engineering leadership within the energy services sector. In his new role, he will oversee TAQA's technology strategy, product innovation, and engineering excellence across our diversified portfolio of solutions. Prior to joining TAQA, Lembcke held senior executive roles at Weatherford International, including Chief Engineer, Director of Engineering Quality, and Vice President of Research, Development, and Engineering. He successfully led complex transformation programs, including integrating over 40 acquisitions, while accelerating innovation cycles and maintaining high operational performance. Lembcke is widely respected for his technical depth and strategic vision. He holds more than 50 US patents in areas such as artificial lift, completions, fiber optics, and production optimization, and has contributed to the development of global industry standards through his long-standing involvement with API and ISO technical committees. He earned a BS in Mechanical Engineering from the University of Oklahoma and an MBA from the University of Tulsa. Lembcke is also known for his strong leadership, mentorship, and passion for building high-performing teams and fostering a culture of innovation, TAQA said. - TradeArabia News Service
Trade Arabia
15-05-2025
- Trade Arabia
Mayo Clinic's manufacturing engineers on the cusp of delivering new biotherapies
Manufacturing engineers are at the forefront of bringing new medicines derived from human sources such as cells, blood and genes to patients, Mayo Clinic has said. They produce what are often first-of-their kind biotherapies for diseases that previously had few or no treatment options. "The most interesting thing about our job is being able to be part of a team that brings transformative cell-based therapies to the clinic," says Kyle Ecker, Advanced Biomanufacturing Engineer Supervisor at Mayo Clinic in Florida. "It's incredibly fulfilling to understand the scientific basis of these therapies and watch them come to life by manufacturing products for individual patients." Mayo Clinic's Center for Regenerative Biotherapeutics has 40 manufacturing engineers in Rochester and Florida. Their work makes it possible for researchers to conduct studies that require cells to be engineered on a very short timeline. In some cases, they've been able to have cells taken from patients, manufactured and returned to them in a few weeks or less. Chimeric antigen receptor (CAR-T) cell therapy for B-cell cancers and a cell-based vaccine for ovarian cancer are two examples of experimental biotherapies manufactured at Mayo Clinic. "Our engineering teams are very dedicated to patients. They know the importance of their job, and that's to get these drugs manufactured successfully so they can be given to patients in clinical trials," says Snigdha Rai, senior director of advanced biomanufacturing in the Center for Regenerative Biotherapeutics. "Without the engineers there would be no biomanufacturing and no cell and gene therapies for patients." Manufacturing engineers work within a highly controlled laboratory setting or "clean room.' Clean rooms are facilities that operate according to current Good Manufacturing Practice (cGMP) regulations to ensure therapies are consistently manufactured and meet strict quality standards. These controlled environments have powerful purification systems to filter out pollutants such as dust, airborne particles, bacteria, fungus and mold that could compromise drug safety. Adherence to strict cleanliness guidelines dictates how engineers do their job. Before stepping into a clean room, they train extensively how to operate in a cGMP facility without triggering contamination. They perform techniques to keep everything extremely clean or sterile, using high dexterity skills such as taking the cap off a vial and putting it back on with one hand, while the other hand fills it with a chemical compound. They dress in coveralls or a "bunny suit" with a hood, goggles, face shield, double gloves and boot covers to block any escape of hair or skin cells. Once they've entered the clean room, their movements are slow and intentional. "Rapid movements or quick opening of doors could trigger the sensors that monitor for microscopic particles," Ecker explains. "People and materials must flow in a specific path to prevent any type of contamination. For example, we move in one direction, entering the clean room through one door while exiting through a separate door." Manufacturing engineers have the pivotal role of being the first to run processes that transform a cell and gene therapy from a discovery into experimental medicine for use in human clinical trials. They strictly follow standard operating procedures — a blueprint of sorts — to mass produce a new therapy. A minimum of two engineers work together at all times to ensure all cells are processed according to regulatory and quality standards. "The team works very closely each step of the way. We check each other's work and keep detailed records confirming that all procedures have been completed," says Qing Cindy Shao, Ph.D., lead advanced biomanufacturing engineer. "There is no room for error." An important function of the job is identifying when a procedure doesn't work as intended. The therapy is then sent back to the investigator and process development group to troubleshoot the issue and make appropriate changes. On-site manufacturing facilities make it possible to address the errors early and resolve them quickly. That helps minimize delays for patients. "Our manufacturing engineers are indispensable. They work with quality control, quality assurance and process development to ensure the therapy meets the requirements and are safe for patients," says Alina Oancea, manager of cGMP manufacturing. "When the processes work as intended, it takes about two weeks to manufacture a CAR-T cell product."
